Search

Displaying results 5391 - 5400 of 9707 in total
  1. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    RAS variants rather than a single mutation. … [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test.

  2. Drug

    BMS-986263

    go.drugbank.com/drugs/DB28821
    Investigational

    BMS-986263 is a biologic drug.

  3. Drug

    Leukocyte Platelet Rich Fibrin

    go.drugbank.com/drugs/DB34000
    Experimental

    Leukocyte Platelet Rich Fibrin is a biologic drug.

    Synonyms: L-prf
  4. Drug

    CITY-RBP4

    go.drugbank.com/drugs/DB34001
    Experimental

    CITY-RBP4 is a biologic drug. CITY-RBP4 is under investigation in clinical trial NCT07836452 (A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants).

  5. Drug

    D-Asparagine

    go.drugbank.com/drugs/DB03943
    Experimental

    A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase.

  6. Drug

    Strontium chloride

    go.drugbank.com/drugs/DB13987
    ApprovedWithdrawn

    Strontium chloride (SrCl2) is a salt of strontium and chloride. … SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168].

  7. Drug

    Indocyanine green

    go.drugbank.com/drugs/DB16024
    ApprovedInvestigationalWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with

  9. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] Sevabertinib was granted accelerated approval by the FDA on November 19th, 2025 for patients who had received a prior systemic therapy. … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain

  10. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    Gadoquatrane is a macrocyclic gadolinium-based contrast agent used to enhance magnetic resonance imaging. … [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity